Details of the Drug

General Information of Drug (ID: DMKUOQV)

Drug Name

Burosumab

Synonyms

Burosumab [USAN]; UNII-G9WJT6RD29; G9WJT6RD29

Indication

Disease Entry	ICD 11	Status	REF
X-linked hypophosphataemia	5C63.22	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Sequence

>heavy chain
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHYMHWVRQAPGQGLEWMGIINPISGSTSN
AQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDIVDAFDFWGQGTMVTVSSAST
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV
FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPGK
>light chain
AIQLTQSPSSLSASVGDRVTITCRASQGISSALVWYQQKPGKAPKLLIYDASSLESGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQFNDYFTFGPGTKVDIKRTVAAPSVFIFPPS
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL
SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 5-10 days [2]
Clearance: The clearance of drug is 0.290 L/day [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 19 days [2]
Metabolism: The drug is metabolized via the hepatic metabolic mechanisms [2]

Cross-matching ID

DrugBank ID: DB14012
TTD ID: D0DJ9D

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor-23 (FGF23)	TT2IZ4K	FGF23_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	Crysvita Drug Label